Skip to main content
. 2013 Dec 2;73(9):1626–1634. doi: 10.1136/annrheumdis-2013-204405

Figure 2.

Figure 2

ACR and DAS28(CRP) response, week 12. (A) ACR20, (B) ACR50, (C) ACR70 at week 12, (D) improvement from baseline, and (E) number of patients in remission defined as DAS28(CRP) <2.6. ACR20/50/70 indicates at least 20%, 50% or 70% improvement in tender and swollen joint counts as well as at least 20%, 50% or 70% improvement in three of the other five ACR components. Panel A shows unadjusted (nominal) p values; *adjusting for multiplicity resulted in significance for the highest dose group as discussed in the text. Unadjusted p values are shown in panels B, C, D and E; Bonferroni adjustment for multiplicity considers p value <0.01 statistically significant. ACR, American College of Rheumatology; DAS28, disease activity score 28 joint count; MTX, methotrexate; q2w, every 2 weeks; qw, every week; SAR, sarilumab.